Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
OrbusNeich Medical Group Holdings Limited ( (HK:6929) ) has shared an update.
OrbusNeich Medical Group Holdings Limited reported a 10.0% year-on-year increase in revenue to US$180.5 million for the year ended December 31, 2025, with gross profit rising 7.0% to US$122.4 million despite some margin compression. Net profit attributable to shareholders grew 5.5% to US$41.9 million, while core operating profit expanded 20.2%, indicating stronger underlying operational performance.
The company’s net profit margin eased slightly to 23.2%, but core operating profit margin improved to 19.3%, reflecting better cost discipline and a healthier core business mix. The board proposed a higher final dividend of HK12 cents per share, up 20.0% from the previous year, signaling confidence in cash generation and offering enhanced returns to shareholders despite increased costs and ongoing investments in research and development.
The most recent analyst rating on (HK:6929) stock is a Hold with a HK$4.50 price target. To see the full list of analyst forecasts on OrbusNeich Medical Group Holdings Limited stock, see the HK:6929 Stock Forecast page.
More about OrbusNeich Medical Group Holdings Limited
OrbusNeich Medical Group Holdings Limited is a medical device company listed in Hong Kong and incorporated in the Cayman Islands, focusing on cardiovascular interventional products. The group generates revenue globally from the development, manufacturing, and sale of specialized devices used in minimally invasive cardiac procedures and related treatments.
Average Trading Volume: 103,040
Technical Sentiment Signal: Sell
Current Market Cap: HK$3B
See more data about 6929 stock on TipRanks’ Stock Analysis page.